Corcept Therapeutics INC Form 4 insider transactions

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on August 1, 2024, according to a recent SEC filing.

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, exercised stock options and sold shares to cover the exercise price and tax obligations on August 1, 2024.

CEO Joseph K. Belanoff exercised stock options and sold shares of Corcept Therapeutics on July 31, 2024, to cover the exercise price and associated tax liabilities.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on July 1, 2024, according to a recent SEC filing.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on July 1, 2024, according to a recent SEC filing.

Gary Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares on July 1, 2024, according to a Form 4 filing with the SEC.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on July 1, 2024, according to a Form 4 filing with the SEC.

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock, including stock grants, transfers, and holdings in custodial accounts.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares to cover the exercise price and tax obligations on June 4, 2024.

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports acquiring and disposing of company stock, including shares withheld for tax obligations and purchases under an incentive plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports the acquisition and disposal of company stock, including transactions under a 10b5-1 plan and a purchase plan.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock at $32 per share on June 3, 2024, according to a recent SEC filing.

Atabak Mokari, CFO of Corcept Therapeutics, reports the acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under a company purchase plan.

Gary Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold 11,000 shares of common stock on May 28, 2024, according to a recent SEC filing.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 30,000 shares of common stock on May 28, 2024, according to a Form 4 filing with the SEC.

Director James N. Wilson reported a gift of 2,000 common stock shares and disclaims beneficial ownership except for pecuniary interest.

Director Kimberly Park acquired 30,000 stock options in Corcept Therapeutics on May 17, 2024, exercisable over a one-year period.

Director Joshua M. Murray of Corcept Therapeutics acquired 30,000 stock options on May 17, 2024, exercisable over a one-year period.

Director Daniel N. Swisher Jr. of Corcept Therapeutics acquired 30,000 stock options on May 17, 2024.

Director Gregg H. Alton of Corcept Therapeutics reported the acquisition of stock options on May 17, 2024.

David Mahoney, a director of Corcept Therapeutics, acquired 30,000 stock options on May 17, 2024.

G Leonard Baker Jr., a director of Corcept Therapeutics, acquired 30,000 stock options on May 17, 2024.

Director Gillian Cannon reports the acquisition of stock options in Corcept Therapeutics.

Director James N. Wilson of Corcept Therapeutics acquired 80,000 employee stock options on May 17, 2024.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold 50,000 shares of Corcept Therapeutics (CORT) common stock at $28 per share on May 13, 2024, under a pre-arranged 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 9, 2024, according to a recent SEC filing.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 2, 2024, according to a recent SEC filing.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on May 1, 2024, according to a Form 4 filing with the SEC.